MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Erasca Inc

Cerrado

1.4 -3.45

Resumen

Variación precio

24h

Actual

Mínimo

1.39

Máximo

1.45

Métricas clave

By Trading Economics

Ingresos

1.3M

-31M

BPA

-0.11

Empleados

103

EBITDA

-750K

-36M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+200.69% upside

Dividendos

By Dow Jones

Próximas Ganancias

8 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-34M

360M

Apertura anterior

4.85

Cierre anterior

1.4

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Erasca Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jul 2025, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

4 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 15:57 UTC

Charlas de Mercado

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 jul 2025, 15:49 UTC

Charlas de Mercado

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Received All Required Authorizations

4 jul 2025, 15:48 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 jul 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Agreement Was Announced on Dec. 19

4 jul 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 jul 2025, 15:46 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 jul 2025, 14:30 UTC

Adquisiciones, fusiones, absorciones

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 jul 2025, 13:53 UTC

Charlas de Mercado

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 jul 2025, 13:41 UTC

Charlas de Mercado

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 jul 2025, 13:41 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 jul 2025, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 12:37 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 jul 2025, 12:37 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 jul 2025, 12:30 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 jul 2025, 12:15 UTC

Charlas de Mercado

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 jul 2025, 12:13 UTC

Charlas de Mercado

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 jul 2025, 12:02 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc Esperado

Precio Objetivo

By TipRanks

200.69% repunte

Estimación a 12 meses

Media 4.33 USD  200.69%

Máximo 6 USD

Mínimo 3 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.39 / 1.44Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Very Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.